top of page

FDA declines approval of Summit and Akeso's ivonescimab for EGFR-mutated lung cancer

Writer: nuaxia
nuaxia
1 day ago
2 min read

The FDA has issued a Complete Response Letter for Summit Therapeutics' ivonescimab in EGFR-mutated lung cancer after the HARMONi trial demonstrated a progression-free survival benefit but did not establish a statistically significant overall-survival benefit.


Summit Therapeutics announced on 15 November 2026 that the US Food and Drug Administration had declined to approve ivonescimab in combination with platinum-containing chemotherapy for patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer following prior EGFR-targeted treatment, issuing a Complete Response Letter in response to the company's biologics licence application.


The decision followed review of the HARMONi clinical trial, which showed improvement in progression-free survival without establishing a statistically significant overall-survival benefit in the submitted analysis; ivonescimab is an investigational PD-1 × VEGF bispecific antibody developed by Akeso and licensed to Summit, and the regulatory setback does not represent a clinical hold or permanent discontinuation of the programme.

Field

Content

Article Type

Approvals

Regulatory Event

FDA Complete Response Letter

Regulatory Outcome

Approval declined

Company

Summit Therapeutics

Originating Developer

Akeso

Investigational Medicine

Ivonescimab

Drug Modality

Bispecific antibody

Molecular Targets

PD-1 and VEGF

Regulatory Authority

US Food and Drug Administration

Announcement Date

15 November 2026

Regulatory Submission

Biologics licence application

Proposed Treatment

Ivonescimab plus platinum-containing chemotherapy

Therapeutic Area

Oncology

Cancer Type

Non-small cell lung cancer

Molecular Subtype

EGFR-mutated

Proposed Patient Population

Patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer following prior EGFR-targeted therapy

Treatment Setting

After prior EGFR-targeted treatment

Supporting Clinical Trial

HARMONi

Progression-Free Survival Finding

Benefit demonstrated

Overall Survival Finding

Statistically significant benefit not established in the submitted analysis

Regulatory Concern

Overall-survival evidence did not establish the required benefit

US Marketing Approval Granted

No

Clinical Hold Imposed

Not reported

Programme Permanently Terminated

Not reported

Commercial Launch Authorised

No

What Happened

The FDA issued a Complete Response Letter declining Summit's application for ivonescimab in EGFR-mutated lung cancer.

Why It Matters

The decision creates a significant regulatory obstacle for a high-profile bispecific antibody programme in lung cancer.

Clinical Significance

The regulatory outcome highlights the importance of overall-survival evidence alongside progression-free survival in oncology development.

Strategic Significance

The setback affects Summit's US development and commercialisation plans for ivonescimab.

Regulatory Clarification

A Complete Response Letter is not an approval and does not necessarily end future development or resubmission.

Key Takeaway

Ivonescimab has not received FDA approval for the submitted EGFR-mutated lung cancer indication.

What to Watch

Summit's response to the FDA, additional survival analyses, potential regulatory discussions and any future resubmission.

Primary Source

Summit Therapeutics

Primary Source URL

https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application-2026.pdf

Submitted Source

Reuters

Submitted Source URL

https://www.reuters.com/legal/litigation/us-fda-declines-approve-summit-lung-cancer-drug-after-trial-misses-key-survival-2026-11-15/

Relevant Date

15 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page